Fortrea Holdings Inc. (FTRE)
| Market Cap | 1.62B +66.8% |
| Revenue (ttm) | 2.68B -2.1% |
| Net Income | -85.20M |
| EPS | -0.92 |
| Shares Out | 95.10M |
| PE Ratio | n/a |
| Forward PE | 18.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,360,444 |
| Open | 17.28 |
| Previous Close | 17.70 |
| Day's Range | 16.86 - 17.61 |
| 52-Week Range | 8.31 - 21.39 |
| Beta | 1.95 |
| Analysts | Buy |
| Price Target | 20.55 (+20.74%) |
| Earnings Date | Jul 29, 2026 |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, ... [Read more]
Financial Performance
In 2025, Fortrea Holdings's revenue was $2.72 billion, an increase of 1.00% compared to the previous year's $2.70 billion. Losses were -$986.20 million, 200.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price target is $20.55, which is an increase of 20.74% from the latest price.
News
Fortrea to buy Worldwide Clinical Trials Early Phase Services division for $45M
Fortrea (FTRE) and Worldwide Clinical Trials announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide’s Early Phase Services division, consisting of its Clinic...
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership...
Fortrea price target raised to $23 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Fortrea (FTRE) to $23 from $19 and keeps a Buy rating on the shares. The firm remains confident in the company’s commercial…
Fortrea price target raised to $22 from $20 at Citi
Citi raised the firm’s price target on Fortrea (FTRE) to $22 from $20 and keeps a Buy rating on the shares.
Fortrea price target raised to $20 from $18 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Fortrea (FTRE) to $20 from $18 and keeps a Hold rating on the shares.
Fortrea price target raised to $23 from $21 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Fortrea (FTRE) to $23 from $21 and keeps an Outperform rating on the shares. The firm updated its model following…
Fortrea price target raised to $22 from $18 at Barclays
Barclays raised the firm’s price target on Fortrea (FTRE) to $22 from $18 and keeps an Equal Weight rating on the shares. The company reported a ‘strong beat across the…
Fortrea price target raised to $25 from $20 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Fortrea (FTRE) to $25 from $20 and keeps an Outperform rating on the shares. Fortrea’s turnaround continues to track,…
Fortrea Holdings Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, with improved full-year guidance and strong commercial momentum, especially in biotech. Revenue declined year-over-year due to lower passthroughs, but adjusted EBITDA and cash flow improved, supported by cost savings and operational efficiencies.
Fortrea Holdings Slides: Q2 2026
Fortrea Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Fortrea Holdings Earnings release: Q2 2026
Fortrea Holdings released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Fortrea Holdings Quarterly report: Q2 2026
Fortrea Holdings has published its Q2 2026 quarterly earnings report on July 29, 2026.
Fortrea reports Q2 adjusted EPS 23c, consensus 18c
Reports Q2 revenue $678.2M, consensus $647.59M. “Our Q2 results reflect continued progress against our strategy and disciplined execution across the business,” said Anshul Thakral, CEO of Fortrea (FTR...
Fortrea Reports Second Quarter 2026 Results
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2...
Fortrea price target raised to $16 from $13 at Mizuho
Mizuho raised the firm’s price target on Fortrea (FTRE) to $16 from $13 and keeps a Neutral rating on the shares. The firm adjusted targets in the healthcare facilities and…
Fortrea CFO Jill McConnell to step down, Jason Knoblauch to succeed
Fortrea (FTRE) announced that Jason Knoblauch has been appointed as chief financial officer, effective July 6. He will succeed Jill McConnell, who is stepping down. Knoblauch joins Fortrea from Clario...
Fortrea Names Jason Knoblauch as Chief Financial Officer
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea
Fortrea price target raised to $18 from $16 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Fortrea (FTRE) to $18 from $16 and keeps an Equal Weight rating on the shares. The firm adjusted targets in…
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of ...
Fortrea Holdings Transcript: AGM 2026
The meeting established a quorum and proceeded with three proposals: election of directors, ratification of the auditor, and advisory approval of executive compensation. All proposals received the requisite votes for approval, with final results to be filed in a Form 8-K.
Fortrea Holdings Transcript: Jefferies Global Healthcare Conference 2026
Demand and bookings are improving across pharma and biotech, with clinical pharmacology rebounding fastest. Revenue is stabilizing, cost savings are on track, and sales strategies are more targeted. AI is a key topic but will take years to impact workflows, while technology upgrades and client diversification support future growth.
Fortrea to Attend Jefferies Global Healthcare Conference
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and S...
Fortrea price target raised to $13 from $11 at Mizuho
Mizuho raised the firm’s price target on Fortrea (FTRE) to $13 from $11 and keeps a Neutral rating on the shares.
Fortrea price target raised to $14 from $11 at Deutsche Bank
Deutsche Bank analyst Justin Bowers raised the firm’s price target on Fortrea (FTRE) to $14 from $11 and keeps a Hold rating on the shares.